Establishment of a standard 14-3-3 protein assay of cerebrospinal fluid as a diagnostic tool for Creutzfeldt–Jakob disease

[1]  H. Kretzschmar,et al.  14-3-3 CSF levels in sporadic Creutzfeldt–Jakob disease differ across molecular subtypes , 2009, Neurobiology of Aging.

[2]  K. Eguchi,et al.  Total Tau Protein in Cerebrospinal Fluid and Diffusion-Weighted MRI as an Early Diagnostic Marker for Creutzfeldt-Jakob Disease , 2007, Dementia and Geriatric Cognitive Disorders.

[3]  K. Eguchi,et al.  Chronological Changes in MRI and CSF Biochemical Markers in Creutzfeldt-Jakob Disease Patients , 2007, Dementia and Geriatric Cognitive Disorders.

[4]  K. Hess,et al.  CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease , 2006, Neurology.

[5]  Y. Itoyama,et al.  14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages , 2006, Journal of clinical neuroscience.

[6]  Tomoyuki N. Tanaka,et al.  Association of an 11-12 kDa protease-resistant prion protein fragment with subtypes of dura graft-associated Creutzfeldt-Jakob disease and other prion diseases. , 2003, The Journal of general virology.

[7]  J. Martín,et al.  A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[8]  D. Lanska Diagnosis of Creutzfeldt–Jakob disease: Effect of clinical criteria on incidence estimates Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease , 2001, Neurology.

[9]  P Brown,et al.  Classification of sporadic Creutzfeldt‐Jakob disease based on molecular and phenotypic analysis of 300 subjects , 1999, Annals of neurology.